PGEN logo

Precigen, Inc. Common Stock


PGEN: Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.


Show PGEN Financials

Consumer Interest
SEC Filings

Recent trades of PGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by PGEN's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Modulating expression of polypeptides via new gene switch expression systems Jul. 04, 2023
  • Patent Title: Hepatitis b vaccines and uses of the same Mar. 21, 2023
  • Patent Title: Fusion constructs and methods of using thereof Dec. 27, 2022
  • Patent Title: Methods and microorganisms for the fermentation of methane to multi-carbon compounds Aug. 23, 2022
  • Patent Title: Muc16 specific chimeric antigen receptors and uses thereof May. 03, 2022
  • Patent Title: Molecular switches Dec. 14, 2021
  • Patent Title: Methods and microorganisms for making 1,4-butanediol and derivatives thereof from c1 carbons Oct. 26, 2021
  • Patent Title: Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies Oct. 26, 2021
  • Patent Title: Expression of novel cell tags Sep. 14, 2021
  • Patent Title: Frataxin expression constructs Sep. 14, 2021
  • Patent Title: Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons Sep. 07, 2021
  • Patent Title: Expression of novel cell tags Jun. 15, 2021
  • Patent Title: Biological production of multi-carbon compounds from methane Dec. 29, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PGEN in WallStreetBets Daily Discussion


Recent insights relating to PGEN

CNBC Recommendations

Recent picks made for PGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PGEN

Corporate Flights

Flights by private jets registered to PGEN